Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Harvard Bioscience, Inc. (HBIO)

2.41   -0.03 (-1.23%) 11-25 13:00
Open: 2.385 Pre. Close: 2.44
High: 2.44 Low: 2.265
Volume: 55,001 Market Cap: 100(M)

Technical analysis

as of: 2022-11-25 1:57:36 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.93     One year: 3.23
Support: Support1: 2.09    Support2: 1.74
Resistance: Resistance1: 2.51    Resistance2: 2.76
Pivot: 2.39
Moving Average: MA(5): 2.36     MA(20): 2.46
MA(100): 2.95     MA(250): 4.41
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 51     %D(3): 41.4
RSI: RSI(14): 48.7
52-week: High: 7.36  Low: 2.09
Average Vol(K): 3-Month: 110 (K)  10-Days: 86 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HBIO ] has closed below upper band by 46.5%. Bollinger Bands are 19.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.49 - 2.5 2.5 - 2.51
Low: 2.39 - 2.4 2.4 - 2.42
Close: 2.42 - 2.44 2.44 - 2.46

Company Description

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Headline News

Wed, 16 Nov 2022
HIROTSU BIO SCIENCE INC.: World's First Test for Early-Stage Pancreatic Cancer, "N-NOSEĀ® plus Pancreas", Now Available - Business Wire

Sat, 12 Nov 2022
Harvard Bioscience, Inc. (HBIO) Q3 2022 Earnings Call Transcript - Seeking Alpha

Tue, 08 Nov 2022
Harvard Bioscience (HBIO) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq

Wed, 02 Nov 2022
Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 ... - The Bakersfield Californian

Thu, 27 Oct 2022
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Profit Outlook - Simply Wall St

Tue, 25 Oct 2022
Harvard Bioscience Stock (HBIO): Undervalued And Underfollowed - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Instruments & Supplies
Shares Out. 42 (M)
Shares Float 34 (M)
% Held by Insiders 11.5 (%)
% Held by Institutions 72.9 (%)
Shares Short 257 (K)
Shares Short P.Month 267 (K)

Stock Financials

EPS -0.17
EPS Est Next Qtl 0.03
EPS Est This Year 0.12
EPS Est Next Year 0.17
Book Value (p.s.) 1.73
Profit Margin (%) -5.9
Operating Margin (%) -3.8
Return on Assets (ttm) -1.9
Return on Equity (ttm) -9.3
Qtrly Rev. Growth -9.2
Gross Profit (p.s.) 1.62
Sales Per Share 2.83
EBITDA (p.s.) 0.07
Qtrly Earnings Growth 0
Operating Cash Flow -1 (M)
Levered Free Cash Flow 8 (M)

Stock Valuations

PE Ratio -14.79
PEG Ratio 2.5
Price to Book value 1.39
Price to Sales 0.85
Price to Cash Flow -71.21

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.